Cellbiotech's probiotic brand DuoLac is accelerating its expansion into the Asian market, leveraging its export base established in 56 countries worldwide. The company aims to discover new partners based on its local business experience in key markets such as Indonesia and Singapore, along with its proprietary probiotic technology.
Cellbiotech announced on September 3 that it is participating in Vitafoods Asia 2026, taking place from September 2 to 4 at the Queen Sirikit National Convention Center in Bangkok. The company has set up an independent booth to showcase its probiotic technology and product portfolio tailored for specific target audiences to global buyers.
Vitafoods Asia is the largest health supplement trade show in Asia, covering the entire health supplement industry, including raw materials, finished products, and distribution. This year, approximately 650 companies and 16,000 visitors are expected to attend.
Cellbiotech is operating a 48-square-meter independent booth at the event, featuring experience zones for different consumer targets, including a Baby Zone, Kids Zone, and Women Zone. This strategy reflects the growing interest in family health and wellness in the Asian market, introducing product lines based on age and health needs.
In particular, the Women Zone will showcase products specialized for women's health, including probiotics for menopause and vaginal health. This expansion aligns with the trend of segmenting the probiotics market, which has traditionally focused on gut health, into functional and target-specific categories.
DuoLac is currently present in 16 Asian countries, including Japan, China, and Taiwan. In Indonesia, where it began local operations in 2001, it holds the top market share. In Singapore, where it entered in 2015, DuoLac has become the leading brand in the ethical pharmaceuticals (ETC) market.
Cellbiotech plans to utilize its long-standing local market experience to explore new markets. The company aims to identify partners that align with consumer demand and regulatory environments across various Asian countries, leveraging its distribution and sales foundations established in Indonesia and Singapore.
A Cellbiotech representative stated, "Through Vitafoods Asia, we will showcase our experience and proprietary technology accumulated in 56 countries to global buyers, strengthening our position in the Asian market by discovering new partners and expanding our export countries."
Meanwhile, DuoLac continues to lead the domestic probiotics export market. From 2013 to 2025, Cellbiotech accounted for approximately 50% of the total cumulative export value of 538.5 billion won in South Korea's probiotics market, recording 268.8 billion won. This achievement has allowed the company to maintain its position as the top exporter of probiotics in South Korea for 13 consecutive years.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.